Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives $8.60 Average PT from Analysts

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have been given a consensus recommendation of “Hold” by the eight ratings firms that are covering the stock, MarketBeat reports. Six research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $4.78.

Several analysts have recently commented on IRWD shares. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $1.00 price objective (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday. Craig Hallum dropped their price target on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. Citizens Jmp downgraded Ironwood Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday. StockNews.com lowered Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Leerink Partners reduced their price objective on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a “market perform” rating for the company in a research note on Monday.

Ironwood Pharmaceuticals Stock Performance

Shares of NASDAQ:IRWD opened at $0.72 on Friday. Ironwood Pharmaceuticals has a 52-week low of $0.59 and a 52-week high of $8.45. The company has a market capitalization of $116.86 million, a PE ratio of -24.07 and a beta of 0.30. The company has a fifty day moving average of $1.50 and a 200-day moving average of $3.08.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.08). The company had revenue of $90.55 million for the quarter, compared to the consensus estimate of $93.85 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. On average, equities analysts forecast that Ironwood Pharmaceuticals will post 0.1 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CMO Michael Shetzline sold 41,269 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $72,633.44. Following the transaction, the chief marketing officer now directly owns 554,007 shares of the company’s stock, valued at approximately $975,052.32. The trade was a 6.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Thomas A. Mccourt sold 139,064 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $244,752.64. Following the completion of the sale, the chief executive officer now directly owns 1,160,634 shares of the company’s stock, valued at approximately $2,042,715.84. This represents a 10.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 192,381 shares of company stock valued at $338,591 over the last quarter. 12.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in IRWD. China Universal Asset Management Co. Ltd. boosted its position in shares of Ironwood Pharmaceuticals by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,932 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 3,209 shares in the last quarter. Quantinno Capital Management LP grew its position in Ironwood Pharmaceuticals by 40.0% in the 3rd quarter. Quantinno Capital Management LP now owns 19,191 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 5,482 shares during the period. Swiss National Bank increased its position in Ironwood Pharmaceuticals by 2.2% during the fourth quarter. Swiss National Bank now owns 282,700 shares of the biotechnology company’s stock valued at $1,252,000 after acquiring an additional 6,000 shares during the last quarter. Teacher Retirement System of Texas increased its holdings in Ironwood Pharmaceuticals by 19.6% during the fourth quarter. Teacher Retirement System of Texas now owns 42,893 shares of the biotechnology company’s stock valued at $190,000 after buying an additional 7,020 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Ironwood Pharmaceuticals in the fourth quarter worth about $36,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.